Comparison · Partial vs full agonist~8 min readUpdated 12 May 2026

7-Hydroxymitragynine vs Morphine

One is a prescription analgesic with 80 years of clinical data. The other is an unregulated consumer product sold at gas stations. They bind the same receptor. That's where the similarity ends.

Table 01 · 7-OH vs. Morphine10 factors

Factor	7-Hydroxymitragynine	Morphine
What it is	Kratom alkaloid, sold as consumer tablets/shots	Opium alkaloid, prescription-only analgesic
Receptor type	Partial mu-opioid agonist — has a ceiling	Full mu-opioid agonist — no ceiling
Binding affinity	~13× morphine in radioligand assays	Baseline reference compound
What '13× stronger' actually means	Grips the receptor 13× tighter — not 13× the effect	Lower affinity but maximal receptor activation
Respiratory depression	Partial-agonist ceiling — softer risk in isolation	Dose-dependent, no ceiling — primary cause of opioid death
Overdose pattern	87 of 91 kratom-attributed deaths involved other substances	Well-characterised fatal overdose dose-curve in monotherapy
Abuse liability	Rats self-administer at morphine-comparable rates	Reference standard for opioid abuse liability
Quality control	Unregulated; label accuracy varies widely	Pharmaceutical-grade; exact dose per unit guaranteed
Medical approval	Not FDA-approved for any use	FDA-approved analgesic since 1941
Legal status (US)	Federally unscheduled; banned or restricted in growing number of states	Schedule II — prescription required

“13× stronger” is a real number with a wrong conclusion

7-OH binds the mu-opioid receptor with roughly 13× the affinity of morphine in radioligand assays (Kruegel 2016). That number appears in every product listing, every Reddit thread, every news segment. What almost never follows: affinity and clinical potency are not the same thing.

7-OH is a partial agonist. It grips the receptor more tightly but produces a submaximal response — its E_maxat the human mu-opioid receptor is about 47%, compared to morphine’s near-100%. In functional antinociception tests (actual pain response in mice), the potency ratio drops to about 5–10× morphine (Matsumoto 2004). And in drug-discrimination assays, rats generalise 7-OH to morphine — confirming it produces morphine-like subjective effects — but with a ceiling that morphine does not have (Obeng 2021).

The safety margin is real. It’s also narrower than you think.

The partial-agonist ceiling on respiratory depression is a genuine pharmacological feature. It’s the same mechanism that makes buprenorphine safer than morphine in monotherapy overdose — the receptor is occupied but the downstream signal can’t climb past a fixed maximum. For 7-OH in isolation, this is real and meaningful.

Three things collapse it:

Polydrug exposure.The overwhelming majority of kratom-involved overdose deaths in US surveillance data involved at least one additional substance. In the CDC’s 2016–2017 analysis, 87 of 91 kratom-attributed deaths involved fentanyl, benzodiazepines, or other depressants (CDC MMWR 2019). The partial-agonist safety margin disappears when the other substances in the mix are full agonists or CNS depressants.
Uncontrolled dose. Morphine is dosed under clinical supervision with titration, monitoring, and naloxone at hand. 7-OH is dosed at home from products whose label accuracy has been documented to vary wildly — the Texas AG found products at 96% 7-OH, 48× the legal limit. At those concentrations, the partial-agonist ceiling is less protective than the marketing implies.
Abuse liability is not reduced. Rats self-administer 7-OH at rates comparable to morphine (Hemby 2019). “Safer respiratory profile” does not mean “less addictive.” These are independent claims, and the evidence supports only the first — and only when other substances are not involved.

7-OH is not a “safer morphine.” It is a different opioid with a different risk profile. The pharmacology is interesting; the consumer-market delivery system is the problem.

What this means for pain patients

About 50 million Americans live with chronic pain. Many have cycled through NSAIDs, gabapentinoids, and prescription opioids — facing either inadequate relief, intolerable side effects, or the increasingly difficult task of getting opioid prescriptions renewed. For some of these people, 7-OH fills a genuine gap: it produces real analgesia via the same receptor, it’s available without a prescription, and it’s legal in most states.

The gap it fills is also a trap. Morphine comes with dosing protocols, overdose-reversal capability, quality-controlled formulations, and a prescriber who knows what you’re taking. 7-OH comes with none of those. If you’re managing chronic pain and considering 7-OH, the honest framing:

It will probably work for pain. The pharmacology supports that.
If you use it daily, tolerance and physical dependence are near-certainties, not possibilities.
A healthcare provider should know you’re taking it — even if they didn’t prescribe it. CYP3A4 interactions with other medications are the most common mechanism for unexpected effects.
Read the dosage guide and start at the absolute bottom. Label milligrams are not always accurate.

Why morphine is Schedule II and 7-OH isn’t (yet)

Morphine has been an FDA-approved analgesic since 1941 and a Schedule II controlled substance since the Controlled Substances Act of 1970. Its dose-response, toxicity, abuse liability, and clinical utility are among the most thoroughly characterised of any drug in pharmacology.

7-OH has no FDA approval, no controlled clinical trials in humans, and no scheduling determination. The FDA recommended Schedule I placement in July 2025— meaning the agency’s position is that 7-OH has high abuse potential and no accepted medical use, which is a stronger classification than morphine’s Schedule II. The DEA has not acted on that recommendation. The consumer market exists in the regulatory gap between “not approved” and “not yet scheduled” — a gap that is closing state by state. The legal tracker shows which states have moved and which are still waiting.

Common questions

05 answers

01Is 7-OH really 13 times stronger than morphine?

At the receptor, yes — 7-OH has roughly 13× the binding affinity of morphine in radioligand assays (Kruegel 2016). But binding affinity and clinical potency are not the same thing. 7-OH is a partial agonist: it grips the receptor more tightly but produces a submaximal response no matter how high the dose climbs. Morphine is a full agonist with no such ceiling. So 7-OH does not produce 13× the pain relief, 13× the euphoria, or 13× the respiratory depression. The '13× stronger' marketing frame is technically accurate for one narrow assay and profoundly misleading for everything that follows from it.

02Is 7-OH safer than morphine?

In one specific way, maybe: the partial-agonist ceiling on respiratory depression is a real pharmacological feature, and it's the same mechanism that makes buprenorphine safer than morphine in monotherapy overdose. But the safety margin collapses with polydrug use (87 of 91 kratom-involved deaths in CDC data involved at least one other substance, usually fentanyl), and abuse liability is not reduced — rats self-administer 7-OH at morphine-comparable rates. Add unregulated manufacturing, variable label accuracy, and no clinical supervision, and '7-OH is safer than morphine' becomes a pharmacology half-truth wrapped in a market failure.

03Can 7-OH replace morphine for chronic pain?

It produces real analgesia via the same receptor — that's not disputed. But morphine is dosed in a clinical setting with titration protocols, overdose-reversal capability (naloxone), quality-controlled formulations, and physician oversight. 7-OH is dosed at home from products with variable potency, no standardised dosing protocol, and no medical supervision. It is also not FDA-approved for any indication. Self-treating chronic pain with an unregulated opioid-receptor agonist carries real risk, especially without a prescriber who knows what you're taking.

04Is 7-OH as addictive as morphine?

The best available preclinical evidence says yes. Rats reliably self-administer 7-OH at rates comparable to morphine (Hemby 2019). In humans, chronic users of concentrated 7-OH products report tolerance escalation within weeks and opioid-type withdrawal (muscle aches, insomnia, irritability, craving) on cessation. The partial-agonist profile that provides a softer respiratory ceiling does not confer a softer dependence profile. 'Safer to overdose on' and 'less addictive' are independent claims, and the evidence supports only the first — and only in monotherapy.

05Why isn't 7-OH a prescription drug if it works on the same receptor?

Because no company has submitted it for FDA approval, which would require Phase I–III clinical trials costing hundreds of millions of dollars. The FDA's July 2025 recommendation went the opposite direction — toward Schedule I placement (no accepted medical use), not toward an approval pathway. The consumer 7-OH market exists in the regulatory gap between 'not approved' and 'not yet scheduled' — a gap that is closing state by state.